Ionis Pharmaceuticals

$55.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.30 (+2.41%) As of 7:48 PM UTC today

Why Robinhood?

You can buy or sell IONS and other stocks, options, and ETFs commission-free!

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA. The listed name for IONS is Ionis Pharmaceuticals, Inc. Common Stock.

CEO
Brett P. Monia
Employees
817
Headquarters
Carlsbad, California
Founded
1989
Market Cap
8.35B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
970.51K
High Today
$56.01
Low Today
$53.00
Open Price
$53.92
Volume
641.91K
52 Week High
$64.37
52 Week Low
$39.32

IONS News

BenzingaFeb 24

Ionis Pharmaceuticals: Q4 Earnings Insights

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share fell 39.10% over

IONS Earnings

-$0.35
$0.21
$0.77
$1.33
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
$0.28 per share
Actual
$0.81 per share
Replay Earnings Call

You May Also Like

OISHY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure